ResearcherBikur Cholim HospitalActive in the last 2 years

Ora Solange Rosengarten

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0000-9274-1866; OpenAlex author ID A5005902146. Sources: ClinicalTrials.gov.

Their work

Papers: 1
Trials: 1 (principal investigator on 1)
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 trial

Papers 1

A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. Co-author DOI 10.1007/s12029-010-9197-1 ↗

Trials 1

Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy Principal investigator NCT06478862 ↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ravit Geva · 1 shared trial, 2024 · strength 0.36
- Trial Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy NCT06478862 ↗
Tali Levy · 1 shared trial, 2024 · strength 0.36
- Trial Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy NCT06478862 ↗
Nirit Yarom · 1 shared trial, 2024 · strength 0.36
- Trial Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy NCT06478862 ↗
Amichai Meirovitz · 1 shared trial, 2024 · strength 0.36
- Trial Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy NCT06478862 ↗
Ruth Peretz · 1 shared trial, 2024 · strength 0.36
- Trial Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy NCT06478862 ↗
Ofer Purim · 1 shared trial, 2024 · strength 0.36
- Trial Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy NCT06478862 ↗
Eileen Mary O'Reilly · 1 shared paper, 2011 · strength 0.02
- Paper A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. DOI 10.1007/s12029-010-9197-1 ↗
Andrew S. Epstein · 1 shared paper, 2011 · strength 0.02
- Paper A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. DOI 10.1007/s12029-010-9197-1 ↗
David Paul Kelsen · 1 shared paper, 2011 · strength 0.02
- Paper A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. DOI 10.1007/s12029-010-9197-1 ↗
Maeve Aine Lowery · 1 shared paper, 2011 · strength 0.02
- Paper A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. DOI 10.1007/s12029-010-9197-1 ↗
Amiel Segal · 1 shared paper, 2011 · strength 0.02
- Paper A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. DOI 10.1007/s12029-010-9197-1 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.